share_log

AbbVie | 8-K: AbbVie Reports First-Quarter 2024 Financial Results

AbbVie | 8-K: AbbVie Reports First-Quarter 2024 Financial Results

艾伯維公司 | 8-K：艾伯維公佈2024年第一季度財務業績
美股sec公告 ·  04/26 19:48
牛牛AI助理已提取核心訊息
On April 26, 2024, AbbVie Inc. reported its financial results for the first quarter ending March 31, 2024. The company announced a slight increase in net revenues to $12.310 billion, up 0.7% on a reported basis and 1.6% on an operational basis. Despite facing competition from Humira biosimilars, which led to a 3.9% decrease in global net revenues from the immunology portfolio, AbbVie saw growth in other areas. The oncology portfolio increased by 9.0% on a reported basis, and the neuroscience portfolio by 15.9%. The aesthetics portfolio experienced a 4.0% decrease. AbbVie's GAAP diluted EPS was $0.77, a significant increase from the previous year, while the adjusted diluted EPS was $2.31, a decrease of 6.1%. The company also completed the acquisition of ImmunoGen, adding the cancer therapy Elahere to its portfolio. AbbVie raised its full-year adjusted diluted EPS guidance from $10.97 - $11.17 to $11.13 - $11.33. Additionally, Robert A. Michael was announced as the new CEO, succeeding Richard A. Gonzalez effective July 1, 2024. The company's shares are traded on the New York Stock Exchange under the ticker ABBV.
On April 26, 2024, AbbVie Inc. reported its financial results for the first quarter ending March 31, 2024. The company announced a slight increase in net revenues to $12.310 billion, up 0.7% on a reported basis and 1.6% on an operational basis. Despite facing competition from Humira biosimilars, which led to a 3.9% decrease in global net revenues from the immunology portfolio, AbbVie saw growth in other areas. The oncology portfolio increased by 9.0% on a reported basis, and the neuroscience portfolio by 15.9%. The aesthetics portfolio experienced a 4.0% decrease. AbbVie's GAAP diluted EPS was $0.77, a significant increase from the previous year, while the adjusted diluted EPS was $2.31, a decrease of 6.1%. The company also completed the acquisition of ImmunoGen, adding the cancer therapy Elahere to its portfolio. AbbVie raised its full-year adjusted diluted EPS guidance from $10.97 - $11.17 to $11.13 - $11.33. Additionally, Robert A. Michael was announced as the new CEO, succeeding Richard A. Gonzalez effective July 1, 2024. The company's shares are traded on the New York Stock Exchange under the ticker ABBV.
2024年4月26日，艾伯維公司公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈淨收入小幅增長至123.10億美元，按報告計算增長0.7％，運營收入增長1.6％。儘管面臨來自Humira生物仿製藥的競爭，導致免疫學產品組合的全球淨收入下降了3.9％，但艾伯維在其他領域仍實現了增長。根據報告，腫瘤學投資組合增長了9.0％，神經科學投資組合增長了15.9％。美學投資組合下降了4.0％。艾伯維的GAAP攤薄後每股收益爲0.77美元，比上年大幅增長，而調整後的攤薄每股收益爲2.31美元，下降6.1％。該公司還完成了對ImmunoGen的收購，將癌症療法Elahere添加到其投資組合中。艾伯維將其調整後的全年攤薄後每股收益預期從10.97美元至11.17美元上調至11.13美元至11.33美元。此外，羅伯特·邁克爾被宣佈爲新任首席執行官，接替理查德·岡薩雷斯，自2024年7月1日起生效。該公司的股票在紐約證券交易所上市，股票代碼爲ABBV。
2024年4月26日，艾伯維公司公佈了截至2024年3月31日的第一季度財務業績。該公司宣佈淨收入小幅增長至123.10億美元，按報告計算增長0.7％，運營收入增長1.6％。儘管面臨來自Humira生物仿製藥的競爭，導致免疫學產品組合的全球淨收入下降了3.9％，但艾伯維在其他領域仍實現了增長。根據報告，腫瘤學投資組合增長了9.0％，神經科學投資組合增長了15.9％。美學投資組合下降了4.0％。艾伯維的GAAP攤薄後每股收益爲0.77美元，比上年大幅增長，而調整後的攤薄每股收益爲2.31美元，下降6.1％。該公司還完成了對ImmunoGen的收購，將癌症療法Elahere添加到其投資組合中。艾伯維將其調整後的全年攤薄後每股收益預期從10.97美元至11.17美元上調至11.13美元至11.33美元。此外，羅伯特·邁克爾被宣佈爲新任首席執行官，接替理查德·岡薩雷斯，自2024年7月1日起生效。該公司的股票在紐約證券交易所上市，股票代碼爲ABBV。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。